Clinical trial · Observational
Metabolic Syndrome and Risk of Chronic Philadelphia Negative Myeloproliferative Neoplasms
NCT07814560CI-TRIAL-00126257MetSaMyeloprofnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
Studying the role of metabolic syndrome in chronic Myeloproliferative neoplasms (MPNs)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Philadelphia Chromosome Negative Chronic Myelogenous Leukemia | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- eligible patients already diagnosed with chronic Philadelphia negative Myeloproliferative Neoplasms
- description
- metabolic syndrome
Primary outcomes (1)
- measure
- relation of metabolic syndrome to clinical course chronic Philadelphia negative Myeloproliferative Neoplasms
- timeFrame
- 6 months
- description
- relation of metabolic syndrome to clinical course chronic Philadelphia negative Myeloproliferative Neoplasms
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * chronic Philadelphia negative Myeloproliferative Neoplasms Exclusion Criteria: * remission
References
Publications (1)
- BACKGROUNDKelem A, Shiferaw E, Adane T. Hematological abnormalities and associated factors among metabolic syndrome patients at the University of Gondar comprehensive specialized hospital, Northwest Ethiopia. PLoS One. 2023 May 25;18(5):e0286163. doi: 10.1371/journal.pone.0286163. eCollection 2023. PMID 37228109